CIK 0001404281 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | ||||
| Net income (USD) | -34.5 M | -22.8 M | ||
| Diluted EPS (USD/shares) | -0.52 | -4.73 | -2.33 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-04 | S-8 | S-8 | |
| 2026-08-13 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-13 | 8-K | 8-K items 2.02,9.01 | 2026-08-13 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-07-31 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-06-22 | 8-K | 8-K items 5.03,5.07,9.01 | 2026-06-18 |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-13 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-13 | 8-K | 8-K items 2.02,9.01 | 2026-05-13 |
| 2026-05-11 | EFFECT | EFFECT items ,, | |
| 2026-05-07 | CORRESP | CORRESP | |
| 2026-05-07 | UPLOAD | UPLOAD | |
| 2026-05-01 | S-3 | S-3 | |
| 2026-04-30 | DEFA14A | DEFA14A | |
| 2026-04-30 | ARS | ARS | 2025-12-31 |
| 2026-04-30 | DEF 14A | DEF 14A | 2026-06-18 |
| 2026-04-27 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-04-21 | PRE 14A | PRE 14A | 2026-06-18 |
| 2026-03-26 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-03-19 | 10-K | 10-K | 2025-12-31 |
| 2026-03-19 | 8-K | 8-K items 2.02,9.01 | 2026-03-19 |
| 2026-02-17 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-02-13 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-01-21 | SCHEDULE 13G/A | SCHEDULE 13G/A |
Forms on file (last 1,000): 4 167, 8-K 116, 3 45, 10-Q 36, SC 13G/A 25, UPLOAD 17, CORRESP 16, DEFA14A 16. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ELDN (0.002 USD), /gw/filings/filings?ticker=ELDN&form=8-K, /gw/filings/facts?ticker=ELDN&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange